Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204052 | 0.98 | EPHX2 (0.45) | EPHX2EPHX1NPSR1ATMTHRB | |
| SCHEMBL26529447 | 0.86 | EPHX1 (0.41) | EPHX2EPHX1NPSR1ATMTHRB | |
| SCHEMBL24033741 | 0.83 | EPHX1 (0.44) | EPHX2EPHX1ATMGLAHPGD | |
| SCHEMBL24033578 | 0.83 | EPHX1 (0.44) | EPHX2EPHX1ATMGLAHPGD | |
| SCHEMBL3668494 | 0.83 | CYP2D6 (0.48) | EPHX1NPSR1ATMTHRBL3MBTL1 | |
| SCHEMBL17185196 | 0.83 | GLA (0.37) | EPHX2GLA | |
| SCHEMBL3537250 | 0.81 | EPHX1 (0.46) | EPHX2EPHX1NPSR1ATMGLA | |
| SCHEMBL1202737 | 0.81 | EPHX2 (0.42) | EPHX2EPHX1NPSR1ATMTHRB | |
| SCHEMBL16439927 | 0.80 | EPHX1 (0.45) | EPHX2EPHX1NPSR1ATMGLA | |
| SCHEMBL16439964 | 0.80 | EPHX1 (0.45) | EPHX2EPHX1NPSR1ATMGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | EPHX2 2919/4885EPHX1 2521/4885NPSR1 2054/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | EPHX2 2819/4885EPHX1 2293/4885NPSR1 1807/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | EPHX2 2721/4885EPHX1 2459/4885NPSR1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.